Published in J Exp Med on March 01, 1991
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
The continuing challenges of leprosy. Clin Microbiol Rev (2006) 4.09
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25
Anti-inflammatory Agents: Present and Future. Cell (2010) 3.13
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med (1998) 2.39
Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect Immun (1992) 2.33
Familial Mediterranean fever. Rheumatol Int (2005) 2.25
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med (2008) 1.97
Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med (1997) 1.70
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med (1992) 1.63
Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med (1996) 1.61
Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 1.61
Tumor necrosis factor production in patients with leprosy. Infect Immun (1992) 1.55
Differential angiogenic regulation of experimental colitis. Am J Pathol (2006) 1.55
Hansen's disease. West J Med (1993) 1.47
Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med (1995) 1.46
The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res (2008) 1.45
Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis (1999) 1.40
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J (2005) 1.33
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol (2002) 1.30
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 1.29
Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol (2013) 1.29
Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol (2009) 1.28
Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med (1996) 1.24
Tumor necrosis factor alpha (TNFalpha) promotes growth of virulent Mycobacterium tuberculosis in human monocytes iron-mediated growth suppression is correlated with decreased release of TNFalpha from iron-treated infected monocytes. J Clin Invest (1997) 1.20
Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun (1996) 1.19
Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1. J Exp Med (1993) 1.19
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence. Infect Immun (1993) 1.16
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut (2005) 1.14
Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol (2000) 1.14
Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol (1997) 1.10
Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol (2004) 1.09
Hansen's Disease--a time for cautious optimism. West J Med (1993) 1.05
Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem (2011) 1.04
Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut (2002) 1.00
Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview. Future Microbiol (2011) 1.00
Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis (2010) 1.00
An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis (1996) 0.98
Can we change the disease biology of multiple myeloma? Leuk Res (2012) 0.98
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol (2007) 0.97
Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun (1999) 0.97
Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta. Am J Physiol Heart Circ Physiol (2010) 0.97
Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol (1998) 0.96
Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A (1996) 0.96
Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol (2015) 0.96
Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil. PLoS One (2011) 0.95
Use of thalidomide in leprosy. BMJ (1991) 0.95
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov (2015) 0.93
A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother (2000) 0.92
Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. PLoS One (2013) 0.92
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis (1994) 0.92
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol (2002) 0.92
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 0.91
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia (2013) 0.91
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1999) 0.91
Zanvil Alexander Cohn 1926-1993. J Exp Med (1994) 0.91
The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats. Br J Pharmacol (2003) 0.90
Antiallodynic Effect of Thalidomide and Morphine on Rat Spinal Nerve Ligation-induced Neuropathic Pain. Korean J Pain (2010) 0.89
Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha. Immunology (2003) 0.88
Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep (2012) 0.88
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) (2013) 0.88
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology (2008) 0.87
The novel mechanism of lenalidomide activity. Blood (2015) 0.86
Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone. Inflammation (2000) 0.86
Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J (2003) 0.86
Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res (2010) 0.86
Thalidomide induces mucosal healing in Crohn's disease: case report. World J Gastroenterol (2011) 0.86
Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.86
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J Gastroenterol (2007) 0.86
Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol (2006) 0.85
Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol (2013) 0.85
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation (2015) 0.84
Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci (2004) 0.84
Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India. PLoS Negl Trop Dis (2011) 0.84
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs (2008) 0.84
Anti-inflammatory effect of α,β-amyrin, a triterpene from Protium heptaphyllum, on cerulein-induced acute pancreatitis in mice. Inflamm Res (2011) 0.84
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol (2012) 0.83
Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. Eur Radiol (2008) 0.83
Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol (2000) 0.82
Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol (2009) 0.82
Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother (2011) 0.82
3,6'-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J Neurochem (2012) 0.82
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1997) 0.82
Biologic therapies for juvenile arthritis. Arch Dis Child (2003) 0.81
Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation (2001) 0.81
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol (2000) 0.81
3-Deazaadenosine analogues inhibit the production of tumour necrosis factor-alpha in RAW264.7 cells stimulated with lipopolysaccharide. Immunology (1996) 0.81
Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol (1999) 0.81
Treatment of pediatric refractory Crohn's disease with thalidomide. World J Gastroenterol (2011) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
Pathogenesis of type II avian adenovirus infection in turkeys: in vivo immune cell tropism and tissue distribution of the virus. J Virol (1996) 0.81
Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J (2010) 0.80
Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation. Open Biochem J (2011) 0.80
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (1986) 9.19
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med (1989) 6.99
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci U S A (1986) 4.69
Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med (1988) 4.67
Tumors secreting human TNF/cachectin induce cachexia in mice. Cell (1987) 4.19
Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods (1984) 4.16
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol (1989) 3.90
Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol (1990) 3.85
Evidence for tumour necrosis factor/cachectin production in cancer. Lancet (1987) 3.66
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Reactions in leprosy. Lepr Rev (1969) 2.51
Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. Proc Natl Acad Sci U S A (1990) 2.46
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. J Immunol (1986) 2.05
Regulation of the expression of IL-6 in human monocytes. J Immunol (1989) 1.64
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med (1962) 1.44
Acylation of monocyte and glomerular mesangial cell proteins. Myristyl acylation of the interleukin 1 precursors. J Clin Invest (1988) 1.25
Thalidomide--effect on T cell subsets as a possible mechanism of action. Int J Lepr Other Mycobact Dis (1985) 1.24
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol (1982) 1.07
The origin and kinetics of mononuclear phagocytes. J Exp Med (1968) 14.96
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88
Endocytosis. Annu Rev Biochem (1977) 11.42
Endocytosis and the recycling of plasma membrane. J Cell Biol (1983) 10.24
The enzymatic iodination of the red cell membrane. J Cell Biol (1972) 8.62
Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J Exp Med (1979) 8.32
The isolation and selected properties of blood monocytes. J Exp Med (1966) 7.78
Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med (1974) 7.58
In vitro synthesis and secretion of lysozyme by mononuclear phagocytes. J Exp Med (1974) 7.43
Membrane flow during pinocytosis. A stereologic analysis. J Cell Biol (1976) 7.20
The interaction of soluble horseradish peroxidase with mouse peritoneal macrophages in vitro. J Cell Biol (1972) 6.64
Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med (1974) 6.60
Increased superoxide anion production by immunologically activated and chemically elicited macrophages. J Exp Med (1978) 6.50
Activation of mononuclear phagocytes: fact, fancy, and future. J Immunol (1978) 6.22
Externally disposed plasma membrane proteins. I. Enzymatic iodination of mouse L cells. J Cell Biol (1975) 5.82
Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med (1979) 5.38
Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A (2001) 5.21
Pinocytosis in fibroblasts. Quantitative studies in vitro. J Cell Biol (1974) 5.15
The regulation of pinocytosis in mouse macrophages. I. Metabolic requirements as defined by the use of inhibitors. J Exp Med (1966) 5.10
The structure and function of monocytes and macrophages. Adv Immunol (1968) 5.06
Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5' noncoding region. Mol Cell Biol (1988) 4.97
The in vitro differentiation of mononuclear phagocytes. V. The formation of macrophage lysosomes. J Exp Med (1966) 4.84
Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J Exp Med (1983) 4.68
Human dendritic cells. Enrichment and characterization from peripheral blood. J Exp Med (1982) 4.49
Income inequality, the psychosocial environment, and health: comparisons of wealthy nations. Lancet (2001) 4.48
The separation, long-term cultivation, and maturation of the human monocyte. J Exp Med (1977) 4.46
Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest (1981) 4.46
Induction of macrophage plasminogen activator by endotoxin stimulation and phagocytosis: evidence for a two-stage process. J Exp Med (1974) 4.45
Studies of the cell surface of mouse dendritic cells and other leukocytes. J Exp Med (1981) 4.36
The macrophage as an effector cell. N Engl J Med (1980) 4.30
Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity. J Exp Med (1978) 4.29
The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ (1972) 4.25
The regulation of pinocytosis in mouse macrophages. II. Factors inducing vesicle formation. J Exp Med (1967) 4.17
Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol (1999) 4.15
Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med (1986) 4.05
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
Relation between income inequality and mortality: empirical demonstration. BMJ (1999) 3.98
Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. J Exp Med (1994) 3.94
The in vitro differentiation of mononuclear phagocytes. 3. The reversibility of granule and hydrolytic enzyme formation and the turnover of granule constituents. J Exp Med (1965) 3.92
Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp Med (1980) 3.88
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
The uptake and digestion of iodinated human serum albumin by macrophages in vitro. J Exp Med (1967) 3.70
The uptake, storage, and intracellular hydrolysis of carbohydrates by macrophages. J Exp Med (1969) 3.66
Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med (1979) 3.61
The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med (1987) 3.61
A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med (1989) 3.58
Effects of concanavalin A on mouse peritoneal macrophages. I. Stimulation of endocytic activity and inhibition of phago-lysosome formation. J Exp Med (1974) 3.52
The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. N Engl J Med (1982) 3.52
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
The in vitro differentiation of mononuclear phagocytes. IV. The ultrastructure of macrophage differentiation in the peritoneal cavity and in culture. J Exp Med (1966) 3.41
[Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. Rev Rhum Mal Osteoartic (1987) 3.40
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci U S A (1985) 3.31
In vitro induction of lysosomal enzymes by phagocytosis. J Exp Med (1970) 3.11
Plasma membrane synthesis in the macrophage following phagocytosis of polystyrene latex particles. J Biol Chem (1972) 3.10
Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med (1975) 3.03
Regulation of arachidonic acid metabolites in macrophages. J Exp Med (1980) 3.00
The pinocytic rate of activated macrophages. J Exp Med (1975) 2.97
Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med (1979) 2.93
Selective iodination and polypeptide composition of pinocytic vesicles. J Cell Biol (1980) 2.91
Phagosome-lysosome fusion. Characterization of intracellular membrane fusion in mouse macrophages. J Cell Biol (1980) 2.83
Mouse spleen lymphoblasts generated in vitro. Recovery in high yield and purity after floatation in dense bovine plasma albumin solutions. J Exp Med (1978) 2.75
The membrane proteins of the vacuolar system. II. Bidirectional flow between secondary lysosomes and plasma membrane. J Cell Biol (1980) 2.69
Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med (1983) 2.61
Mutational analysis of upstream AUG codons of poliovirus RNA. J Virol (1988) 2.55
Staphylococcus aureus RN6390 replicates and induces apoptosis in a pulmonary epithelial cell line. Infect Immun (2000) 2.54
Mouse peritoneal macrophages release leukotriene C in response to a phagocytic stimulus. Proc Natl Acad Sci U S A (1980) 2.53
The macrophage. Int Rev Cytol (1973) 2.52
The selective inhibition of macrophage phagocytic receptors by anti-membrane antibodies. J Exp Med (1972) 2.51
Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc Natl Acad Sci U S A (1989) 2.50
The fate of peptides pinocytosed by macrophages in vitro. J Exp Med (1969) 2.49
Prostaglandin synthesis by macrophages requires a specific receptor-ligand interaction. Proc Natl Acad Sci U S A (1980) 2.49
Internalization and degradation of macrophage Fc receptors during receptor-mediated phagocytosis. J Cell Biol (1983) 2.49
The membrane proteins of the vacuolar system I. Analysis of a novel method of intralysosomal iodination. J Cell Biol (1980) 2.48
The interaction of particulate horseradish peroxidase (HRP)-anti HRP immune complexes with mouse peritoneal macrophages in vitro. J Cell Biol (1972) 2.48
Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med (1990) 2.42
Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature (1986) 2.41
The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med (1976) 2.41
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med (1998) 2.39
Externally disposed plasma membrane proteins. II. Metabolic fate of iodinated polypeptides of mouse L cells. J Cell Biol (1975) 2.39
Aggregation of complement receptors on human neutrophils in the absence of ligand. J Cell Biol (1987) 2.38
Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell (1986) 2.38
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med (1985) 2.37
Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J Exp Med (1986) 2.34
The regulation of pinocytosis in mouse macrophages. IV. The immunological induction of pinocytic vesicles, secondary lysosomes, and hydrolytic enzymes. J Exp Med (1967) 2.29
Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J Immunol (1987) 2.27
Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J Exp Med (1983) 2.24
5'-Nucleotidase activity of mouse peritoneal macrophages. I. Synthesis and degradation in resident and inflammatory populations. J Exp Med (1976) 2.21
The alveolar macrophage. J Appl Physiol (1985) (1986) 2.21
Stimulus-dependent myristoylation of a major substrate for protein kinase C. Nature (1988) 2.21
The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities. Science (1986) 2.21
Properties of the major outer membrane protein from Neisseria gonorrhoeae incorporated into model lipid membranes. Proc Natl Acad Sci U S A (1983) 2.20
Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect Immun (1997) 2.19